Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
|Articles|September 16, 2021
Pharmacy Clinical Pearl of the Day: Multiple Sclerosis
Author(s)Saro Arakelians, PharmD
In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.
Advertisement
Clinical Pearl of the Day: Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the brain and spinal cord.
Explanation:
- In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.
- Symptoms of MS include numbness, weakness, tremor, lack of coordination, blurry vision, double vision, slurred speech, fatigues, dizziness, tingling, and problems with bowel and bladder function.
- Diagnosis could include blood test, spinal tap, MRI, and an evoked potential test.
- Treatment options may include Interferon beta, Copaxone, Gilenya, Tecfidera, Vumerity, Aubagio, Mayzent, Mavenclad, Ocrevus, Tysarbi, Lemtrada, and physical therapy.
References
Advertisement
Related to this article
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
3
Long-Term Care Pharmacies Can Close the Flu Vaccination Gap Among Older Adults
4
Narrow Therapeutic Index Chemotherapy Dosing With eGFR: Safeguards for Oncology Pharmacists
5